Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics Inc (PTIX) is a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics targeting stress-related neuropsychiatric and mood disorders. This page serves as the definitive source for official company updates, providing investors and researchers with timely access to validated information about PTIX's scientific advancements and operational developments.
Visitors will find curated press releases covering clinical trial progress, regulatory milestones, research publications, and strategic partnerships. Key focus areas include updates on lead candidate PT00114 – a synthetic TCAP analog designed to modulate stress response systems – along with pipeline developments in anxiety, depression, and PTSD therapeutics.
The resource prioritizes factual reporting on preclinical studies, IND submissions, trial phase transitions, and peer-reviewed data disclosures. Content is organized to highlight material events while maintaining compliance with financial disclosure standards. Regular updates ensure stakeholders can track the company's progress in advancing peptide-based CNS therapies through clinical validation stages.
Bookmark this page for direct access to Protagenic Therapeutics' latest announcements, or subscribe to receive email alerts when new developments occur in this innovative neurotherapeutic research space.
Protagenic Therapeutics has announced a 1-for-14 reverse stock split of its common stock, effective May 5, 2025. This strategic move aims to maintain Nasdaq compliance with minimum bid price requirements.
The split will reduce outstanding shares from approximately 8.2 million to 588,750. Trading will continue under the symbol PTIX with a new CUSIP number (74365N301). Key points include:
- Stockholder approval received on April 18, 2025, for a ratio range of 1-for-10 to 1-for-20
- Automatic conversion: 14 current shares will convert to 1 new share
- Fractional shares will be rounded up to the next whole share
- Proportionate adjustments will apply to exercise prices and equity awards
Equiniti Trust Company, the transfer agent, will handle the conversion process. Book-entry holders require no action, while certificate holders will receive instructions via mail for share conversion.
Protagenic Therapeutics (NASDAQ:PTIX) has closed a private placement raising $1.275 million in gross proceeds. The offering included 1,948,295 shares of common stock and two series of warrants. Each series includes 1,948,295 warrants with an exercise price of $0.64 per share. Series A warrants have an 18-month term, while Series B warrants extend for 5 years. The purchase price was set at $0.64 per share ($0.89 for insiders). The company plans to use the proceeds for working capital purposes. Brookline Capital Markets acted as the sole placement agent.
Protagenic Therapeutics (Nasdaq:PTIX) has announced a private placement offering to raise $1.275 million in gross proceeds. The company will issue 1,948,295 shares of common stock at $0.64 per share ($0.89 for insiders), along with series A and B warrants. The series A warrants have an 18-month term while series B warrants extend for 5 years, both with an exercise price of $0.64 per share. Brookline Capital Markets is serving as the sole placement agent. The offering is expected to close by November 4, 2024, with proceeds intended for working capital purposes.
Protagenic Therapeutics (NASDAQ: PTIX) announced promising safety results from the single dose portion of its Phase 1 trial for PT00114, a stress-regulating peptide. The trial involved 30 subjects across five cohorts who received doses up to 1,000 micrograms. No clinically-relevant adverse events were reported. PT00114 aims to address stress, a key factor in psychiatric disorders such as PTSD, depression, anxiety, addiction, and potentially obesity. The multiple dose portion of the trial will commence later this year. An investor call is scheduled for May 22, 2024, at 10:00 am ET to discuss these findings.
Protagenic Therapeutics, Inc. completes enrollment in the single dose portion of Phase 1 trial for PT00114, a synthetic stress-regulating peptide, showing outstanding tolerability. The trial aims to revolutionize treatment for neuropsychiatric disorders like anxiety, depression, PTSD, and addiction. Data from the safety trial phase are expected in May.
FAQ
What is the current stock price of Protagenic Therapeutics (PTIX)?
What is the market cap of Protagenic Therapeutics (PTIX)?
